ARTICLE | Strategy
PI(3)King AbbVie
How AbbVie, Infinity plan to make the most of duvelisib's best-in-class potential
September 8, 2014 7:00 AM UTC
Job one for Infinity Pharmaceuticals Inc. and new partner AbbVie Inc. will be to carve out a niche for Infinity's duvelisib in chronic lymphocytic leukemia, which is fast becoming a crowded market. Infinity is banking on the compound's potential to be best in class, as well as AbbVie's ability to translate its commercial success in the autoimmune market to cancer.
On Sept. 3, Infinity announced the companies will co-develop and co-commercialize duvelisib. The oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma is in Phase III testing for relapsed or refractory CLL and Phase II testing for indolent non-Hodgkin's lymphoma (NHL)...